MeiraGTx Holdings plc Ordinary Shares (MGTX) is a publicly traded Healthcare sector company. As of July 7, 2026, MGTX trades at $14.79 with a market cap of $1.29B and a P/E ratio of -9.60. MGTX moved +6.41% today. Year to date, MGTX is +76.49%; over the trailing twelve months it is +84.95%. Its 52-week range spans $4.55 to $14.42. Analyst consensus is strong buy with an average price target of $27.50. Rallies surfaces MGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MeiraGTx Secures $400M from Oberland for AAV2-hAQP1 and Bota-vec: MeiraGTx secured a $400 million strategic investment from Oberland Capital, comprising $375 million in non-dilutive royalty funding and $25 million in equity to advance AAV2-hAQP1, botaretigene sparoparvovec and AAV-AIPL1 programs. The initial $135 million tranche includes $125 million for capped low single-digit royalties and a $10 million equity infusion.
| Metric | Value |
|---|---|
| Price | $14.79 |
| Market Cap | $1.29B |
| P/E Ratio | -9.60 |
| EPS | $-1.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.42 |
| 52-Week Low | $4.55 |
| Volume | 393.81K |
| Avg Volume | 0 |
| Revenue (TTM) | $79.76M |
| Net Income | $-120.53M |
| Gross Margin | 0.00% |
5 analysts cover MGTX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.50.